- World Health Organization [WHO]. (2013). A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013 (No. WHO/DCO/WHD/2013.2). World Health Organization. https://doi.org/10.1136/bmj.1.4815.882-a.
- Dennis H Lau, Stanley Nattel , Jonathan M Kalman , Prashanthan Sanders. Modifiable Risk Factors and Atrial Fibrillation. Review Circulation. 2017 Aug 8;136(6):583-596. doi: 10.1161/CIRCULATIONAHA.116.023163.
- Paul K Whelton, Robert M Carey, Wilbert S Aronow, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Review Hypertension. 2018 Jun;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066. Epub 2017 Nov 13.
- Zieman SJ, Melenovsky V, Kass DA. (2005). Mechanisms, pathophysiology, and therapy of arterial stiffness. Arteriosclerosis Thrombosis Vascular Biology 25 (5): 932–43.
- Lloyd-Sherlock, P., Beard, J., Minicuci, N., Ebrahim, S., & Chatterji, S. (2014). Hypertension among older adults in low-and middle-income countries: prevalence, awareness and control. International journal of epidemiology, 43(1), 116-128. https://doi.org/10.1093/ije/dyt215
- World Health Organization [WHO]. (2014). Global status report on noncommunicable diseases 2014. World Health Organization, p. 176.
- Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J. and He, J. (2016). Global disparities of hypertension prevalence and control. Circulation, 134, 441–450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912.
- Wolz, M., Cutler, J., Roccella, E. J., Rohde, F., Thom, T., & Burt, V. (2000). Statement from the national high blood pressure education program: prevalence of hypertension.American Journal of Hypertension, 13(1), 103-104. https://doi.org/10.1016/S0895-7061(99)00241-1.
- Cutler, J. A., Sorlie, P. D., Wolz, M., Thom, T., Fields, L. E., & Roccella, E. J. (2008). Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension, 52(5),https://doi.org/10.1161/HYPERTENSIONAHA.108.113357
- Fryar, C. D., Ostchega, Y., Hales, C. M., Zhang, G., & Kruszon-Moran, D. (2017). Hypertension Prevalence and Control Among Adults: United States, 2015-2016. NCHS data brief, (289), 1-8.
- Giuseppe Schillacia,b, Giacomo Puccia,b, and Stefano Perlin. From hypertension to hypertrophy to heart failure:the role of cardiotrophin-1. Journal of Hypertension 2013, 31:474–476. DOI:10.1097/HJH.0b013e32835ed4bb.
- Pemberton CJ, Raudsepp SD, Yandle TG,Cameron VA, Richards AM. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res. 2005; 68: 109-17.
- Pan J, Fukuda M, Saito K, Matsuzaki J, Kodama H, Sano M. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res. 1999; 84: 1127-36.
- Fukuzawa J, Booz JG, Hunt RA, et al. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension. 2003; 5: 1191-96.
- Lopez-Andres N, Inigo C, Gallego I, Dýez J,Fortuno M. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinol. 2008; 149: 4970-78.
- Funamoto M, Hishinuma S, Fujio Y, Matsuda Y, Kunisada K, Oh H. Isolation and characterization of the murine cardiotrophin-1 gene: expression and norepinephrine-induced transcriptional activation. J Mol Cell Cardiol.2000; 32: 1275-84.
- Janjua S, Lawrence KM, Ng LL, Latchman DS. The cardioprotective agent urocortin induces expression of CT-1. Cardiovasc Toxicol. 2003; 3: 255-62.
- Jiang ZS, Jeyaraman M, Wen GB, et al. Highbut not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1. J Mol Cell Cardiol. 2007; 42: 222-33.
- Liu J, Liu Z, Huang F, Xing Z, Wang H, Li Z. Pioglitazone inhibits hypertrophy induced by high glucose and insulin in cultured neonatal rat cardiomyocytes. Pharmazie. 2007; 62: 925-29.
- Hishinuma S, Funamoto M, Fujio Y, Kunisada K, Yamauchi- Takihara K. Hypoxic stress induces cardiotrophin-1 expression incardiac myocytes. Biochem Biophys Res Commun. 1999; 264: 436-40.
- Lopez B, Castellano J, MGonzalez A, Barba J, Dýez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension. 2007; 50: 977-83.
- Takuya Watanabe, Hanae Konii and Kengo Sato. Emerging Roles of Cardiotrophin-1 in the Pathogenesis and Biomarker of Atherosclerosis. www.mdpi.com/journal/jjournal. J 2018, 1, 94–105; doi:10.3390/j1010010.
- Gkaliagkousi, E.; Gavriilaki, E.; Chatzopoulou, F.; Anyfanti, P.; Triantafyllou, A.; Petidis, K.; Zamboulis, C.; Douma, S. Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension. Am. J. Hypertens. 2014, 27, 651–655.
- Song, K.; Wang, S.; Huang, B.; Luciano, A.; Srivastava, R.; Mani, A. Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: A meta-analysis. J. Clin. Hypertens. 2014, 16, 686–692.
- López, B.; González, A.; Querejeta, R.; Barba, J.; Díez, J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. J. Hypertens. 2009, 27, 418–424.
- López, B.; González, A.; Querejeta, R.; Larman, M.; Rábago, G.; Díez, J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014, 63, 483–489.
- Amooali N, Daryanoosh F, Babaee Baigi MA, Mohamadi M. The Impact of 12 Weeks of Aerobic Exercise on SerumLevels of Cardiotrophin-1, Blood Pressure and Left Ventricular Hypertrophy in Hypertensive Elderly Women. Journal of Advances in Medical and Biomedical Research.2016,26.
- PAN Tong-bin,WANG Ya-yi,ZUO Wei,TANG Fang. (2012). The Changes of Cardiac Muscle Ultrastructure and Cardiotrophin-1 during Heavy Load Exercise and Recovery in Rats. Journal of Beijing Sport University,12.
- Luis Gamella-Pozuelo, BSc, Isabel Fuentes-Calvo, PhD, Manuel A. Go´mez-Marcos, MD, PhD,Jose´ I. Recio-Rodriguez, BSc, Cristina Agudo-Conde, BSc, Jose´ L. Ferna´ndez Martı´n, PhD,Jorge B. Cannata-Andı´a, MD, PhD, Jose´ M. Lo´pez-Novoa, PhD, Luis Garcı´a-Ortiz, MD, Phd and Carlos Martı´nez-Salgado, PhD(2015).Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk. Medicine _ Volume 94, Number 30, July 2015.
- Giuseppe Limongelli;Paolo Calabrò;Valeria Maddaloni;Antonio Russo;Daniele Masarone;Antonello D’Aponte;Teo Roselli;Rosa Bonauro;Raffaella D’Alessandro;Antonello D’Andrea;Giuseppe Pacileo;Francesco Limongelli;Raffaele Calabro(2010). Cardiotrophin-1 and TNF-α circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. Cytokine. Volume 50, Issue 3, June 2010, Pages 245-247. https://doi.org/10.1016/j.cyto.2009.12.007.
|